Výsledky vyhledávání - "Lauren M Lucas"

Akademický článek

Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics.

Publikováno v: PLoS ONE, Vol 15, Iss 12, p e0243901 (2020)

Whereas recent clinical studies report metastatic melanoma survival rates high as 30-50%, many tumors remain nonresponsive or become resistant to current therapeutic strategies. Analyses of The Cancer Genome Atlas (TCGA) skin cutaneous melanoma (SKCM

Externí odkaz: https://doaj.org/article/b577cffb2bf84042b2d2698e0a334423

Zobrazit plný text záznamu

Plný text ve formátu HTML

ERBB4 Mutant Alleles May Drive BRAF WT Melanomas

Autor: Lauren M. Lucas, Richard L. Cullum, Jessica A. Markham, Joelle N. Woggerman, Vipasha Dwivedi, Rania H. Mohamedelhassan, Laura J. Cook, Connor M. Kelley, Elizabeth L. Knerr, David P. Kaufmann, Megan A. Jacobi, Darby C. Taylor, Cristina C. Rael, Damien S. Waits, Taraswi M. Ghosh, Kenneth M. Halanych, Ram B. Gupta, David J. Riese

Metastatic skin cutaneous melanomas that contain wild-type BRAF alleles (“BRAF WT melanomas”) remain a significant clinical challenge, primarily because of the paucity of targets for therapeutic intervention. In prior work, in silico analyses of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::56774191e9e618b913c9fdf142257902
https://doi.org/10.1101/2022.06.21.22276707

Zobrazit plný text záznamu

Abstract 4000: ERBB4 is sufficient and necessary for proliferation of BRAF WT melanoma cell lines

Autor: Lauren M. Lucas, Vipasha Dwivedi, Rania H. Mohamedelhassan, Erin L. Harrell, Connor M. Kelley, Elizabeth L. Knerr, Jessica A. Markham, David J. Riese

Publikováno v: Cancer Research. 82:4000-4000

Approximately 50% of metastatic melanomas possess wild-type (WT) BRAF alleles. These BRAF-WT tumors are a significant clinical problem, despite the fact that these tumors commonly possess mutations in NF1 or RAS genes, as there are no targeted therap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f20b0d134ce7863fbff592d8d54686be
https://doi.org/10.1158/1538-7445.am2022-4000

Zobrazit plný text záznamu

Abstract 814: Identification of ERBB4 mutant alleles that function as tumor drivers

Autor: Stephen Miller, Lauren M. Lucas, Jessica Markham, Elizabeth Knerr, Joely Burgess, Vipasha Dwivedi, Connor Kelley, David J. Riese

Publikováno v: Cancer Research. 81:814-814

Introduction: ERBB4 (HER4) is a member of the ERBB family of receptor tyrosine kinases, which includes the epidermal growth factor receptor (EGFR/ERBB1/HER1), ERBB2 (Neu/HER2), and ERBB3 (HER3). EGFR and ERBB2 are well-validated targets in a variety

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7d249f7da1c78b311b64d4f547bdb31c
https://doi.org/10.1158/1538-7445.am2021-814

Zobrazit plný text záznamu

Abstract A19: Discovery and characterization of selective and nonselective inhibitors of ErbB4 signaling: Putative targeted melanoma therapeutics

Autor: Mackenzie H. Harris, Laura J. Cook, Ram B. Gupta, David J. Riese, Allan E. David, John T. Piazza, Darby C. Taylor, Richard L. Cullum, David Z. Kaufmann, Cristina C. Rael, Logan Neel, Lauren M. Lucas, Jared I. Senfeld

Publikováno v: Cancer Research. 80:A19-A19

Introduction: Gain-of-function mutations in the gene that encodes the ErbB4 receptor tyrosine kinase have been found in a significant fraction of melanoma samples. Melanoma cell lines that harbor some of these mutations are dependent on ErbB4 for pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::08654f96538007851a62489eba1d7884
https://doi.org/10.1158/1538-7445.mel2019-a19

Zobrazit plný text záznamu

Abstract A21: Identification of putative melanoma driver mutations in the ErbB4 receptor tyrosine kinase gene

Autor: David J. Riese, Kenneth M. Halanych, Richard L. Cullum, Taraswi Mitra Ghosh, Lauren M. Lucas, Damien S. Waits

Publikováno v: Cancer Research. 80:A21-A21

Introduction: Despite the advances in targeted therapies and immunotherapeutics, the 5-year survival rate of metastatic melanoma patients remains about 20%. In part, the high mortality rate is due to the fact that there are currently no other clinica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cfe33ebf26a3f0dc15b553e2d5c73a02
https://doi.org/10.1158/1538-7445.mel2019-a21

Zobrazit plný text záznamu

Abstract 5932: Targeting BRAF WT metastatic melanomas: Identifying ERBB4 mutations as biomarkers for novel combinatorial treatment strategies

Autor: Cristina C. Rael, Allan E. David, Laura J. Cook, Kenneth M. Halanych, David J. Riese, Jessica Markham, Lauren M. Lucas, David P. Kaufmann, Richard L. Cullum, Taraswi Mitra Ghosh, Damien S. Waits

Publikováno v: Cancer Research. 80:5932-5932

Introduction: The treatment of metastatic melanoma (MM) has been dramatically improved through the use of BRAF and MEK inhibitors in patients whose tumors harbor activating mutations in BRAF. However, these mutations occur in only ~50% of MMs and a t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d92d5c7f1dfdcfe3984c3a02a34f57b8
https://doi.org/10.1158/1538-7445.am2020-5932

Zobrazit plný text záznamu

Abstract A159: Characterization of putative ErbB4 antagonists: targeted melanoma drug discovery

Autor: Ram B. Gupta, Richard L. Cullum, Allan E. David, John T. Piazza, David J. Riese, Logan Neel, Lauren M. Lucas, Jared I. Senfeld

Publikováno v: Molecular Cancer Therapeutics. 17:A159-A159

Introduction: Gain-of-function mutations in the ErbB4 receptor tyrosine kinase have been found in a significant fraction of melanoma cell lines that are dependent on ErbB4 for proliferation. However, there is a scarcity of therapeutics for treating t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::59edd5a307c0c93abed44d6f5865b8bf
https://doi.org/10.1158/1535-7163.targ-17-a159

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání